ネルフィナビル
参考資料

↑  “Viracept (nelfinavir mesylate) Tablets and Oral Powder, for Oral Use. Full Prescribing Information”.   ViiV Healthcare Company. Research Triangle Park, NC 27709. 23 November 2015閲覧。
↑  “Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities”. Antimicrob. Agents Chemother. 45 (4):  1086–93. (April 2001). doi:10.1128/AAC.45.4.1086-1093.2001. PMC 90428. PMID 11257019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90428/.
↑  Fischer, Jnos; Ganellin, C. Robin (2006) (英語). Analogue-based Drug Discovery. John Wiley & Sons. p. 510. ISBN 9783527607495. https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA510
1 2  “抗HIV薬選択の基本 - 抗HIV治療ガイドライン  プロテアーゼ阻害剤（PI）の表”. www.haart-support.jp.   HIV感染症及びその合併症の課題を克服する研究班（エイズ対策政策研究事業）. 2021年3月29日閲覧。
↑  “１ヶ月以内に更新された添付文書情報 削除分の表（ビラセプト錠250mg）”. www.info.pmda.go.jp.   PMDA. 2021年3月29日閲覧。
1 2  Shim, JS; Liu, JO (2014). “Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs”. Int. J. Biol. Sci. 10 (7):  654–63. doi:10.7150/ijbs.9224. PMC 4081601. PMID 25013375. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081601/.
↑  Ambinder, Richard F.; Dennis, Phillip A.; Gibson, Wade; Shirley, Courtney M.; Desai, Prashant J.; Kalu, Nene N. (15 May 2014). “Nelfinavir Inhibits Maturation and Export of Herpes Simplex Virus 1”. Journal of Virology 88 (10):  5455–5461. doi:10.1128/JVI.03790-13. PMC 4019105. PMID 24574416. https://jvi.asm.org/content/88/10/5455.
↑  Vieira, Jeffrey; Lagunoff, Michael; Casper, Corey; Corey, Lawrence; Geballe, Adam P.; Gray, Matthew; Gachelet, Eliora; Ikoma, Minako et al. (1 June 2011). “The HIV Protease Inhibitor Nelfinavir Inhibits Kaposi's Sarcoma-Associated Herpesvirus Replication In Vitro”. Antimicrobial Agents and Chemotherapy 55 (6):  2696–2703. doi:10.1128/AAC.01295-10. PMC 3101462. PMID 21402841. https://aac.asm.org/content/55/6/2696.
↑  Ohashi, Hirofumi; Watashi, Koichi; Saso, Wakana; Shionoya, Kaho; Iwanami, Shoya; Hirokawa, Takatsugu; Shirai, Tsuyoshi; Kanaya, Shigehiko et al. (2020-04-15) (英語). Multidrug treatment with nelfinavir and cepharanthine against COVID-19. doi:10.1101/2020.04.14.039925. http://biorxiv.org/lookup/doi/10.1101/2020.04.14.039925.
↑  “Anti-HIV drugs for cancer therapeutics: back to the future?”. Lancet Oncol 10 (1):  61–71. (2009). doi:10.1016/S1470-2045(08)70334-6. PMID 19111246.
↑  Gills, JJ; Lopiccolo, J; Tsurutani, J; Shoemaker, RH; Best, CJM; Abu-Asab, MS; Borojerdi, J; Warfel, NA et al. (September 2007). “Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo”. Clinical Cancer Research 13 (17):  5183–94. doi:10.1158/1078-0432.CCR-07-0161. PMID 17785575. http://clincancerres.aacrjournals.org/content/13/17/5183.full.pdf+html.
↑  “HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.”. Cancer Research 67 (22):  10920–8. (2007). doi:10.1158/0008-5472.CAN-07-0796. PMID 18006837. http://cancerres.aacrjournals.org/content/67/22/10920.long.
↑  Yang, Y; Ikezoe, T; Takeuchi, T; Adachi, Y; Ohtsuki, Y; Takeuchi, S; Koeffler, HP; Taguchi, H (July 2005). “HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling”. Cancer Science 96 (7):  425–33. doi:10.1111/j.1349-7006.2005.00063.x. PMID 16053514.
↑  Koltai T. (2015). “Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity.”. F1000Res 4 (2):  9. doi:10.12688/f1000research.5827.2. PMC 4457118. PMID 26097685. http://f1000research.com/articles/4-9/v2.
↑  “Search of: Nelfinavir cancer - List Results - ClinicalTrials.gov”. clinicaltrials.gov. 2021年4月2日閲覧。
↑  “Search of: Nelfinavir - Phase 3 - List Results - ClinicalTrials.gov”. clinicaltrials.gov. 2021年4月2日閲覧。
1 2  “HIV protease inhibitors block streptolysin S production”. ACS Chemical Biology 10 (5):  1217–26. (2015). doi:10.1021/cb500843r. PMC 4574628. PMID 25668590. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574628/.
↑  “Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease”. Journal of Medicinal Chemistry 40 (24):  3979–3985. (1997). doi:10.1021/jm9704098. PMID 9397180.
↑  “ネルフィナビルの薬効分類・効果・副作用｜根拠に基づく医療情報データベース【今日の臨床サポート】”. clinicalsup.jp. 2021年4月2日閲覧。
↑  Press release from the European Medicines Agency regarding possible genotoxic ethyl mesylate contamination
↑  “「ビラセプト錠に関する重要なお知らせ」について”.   鳥居薬品株式会社. 2021年4月2日閲覧。